Loading
Led ADMIRAL, which made gilteritinib the standard for relapsed FLT3-mutant AML.
Alexander Perl was principal investigator of ADMIRAL, which showed the FLT3 inhibitor gilteritinib doubles survival versus salvage chemotherapy in relapsed or refractory FLT3-mutant AML, the first randomised trial to establish single-agent targeted therapy in the disease. He led the earlier phase 1/2 gilteritinib study and studies of resistance to FLT3 inhibition. He leads AML clinical research at Penn.
Shares FLT3, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tags aml, flt3.
Shares Acute myeloid leukaemia and the tags aml, targeted-therapy.
Shares FLT3, Acute myeloid leukaemia and the tag aml.
Shares FLT3, Acute myeloid leukaemia, Small-molecule kinase inhibitors.
Shares FLT3, Acute myeloid leukaemia and the tag flt3.
Shares FLT3, Acute myeloid leukaemia.
Shares FLT3, Acute myeloid leukaemia and the tag flt3.
Shares FLT3, Acute myeloid leukaemia, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/